Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib
- 31 January 2009
- journal article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 7 (1), 20-23
- https://doi.org/10.3816/cgc.2009.n.003
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responsesBlood, 2008
- Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylationLeukemia, 2008
- Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapyBritish Journal of Dermatology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitorClinical and Experimental Dermatology, 2006
- Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classificationJournal of Cutaneous Pathology, 2006
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Mycosis fungoides-like reaction in a patient treated with GleevecJournal of Cutaneous Pathology, 2003